あすか製薬ホールディングスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/03/25 | 2,120 | 2,142 | 2,112 | 2,125 | ±0 | ±0% | 35,500 |
| 2024/03/22 | 2,144 | 2,147 | 2,120 | 2,125 | -19 | -0.9% | 28,800 |
| 2024/03/21 | 2,137 | 2,158 | 2,130 | 2,144 | +2 | +0.1% | 33,000 |
| 2024/03/19 | 2,125 | 2,149 | 2,113 | 2,142 | +25 | +1.2% | 31,000 |
| 2024/03/18 | 2,144 | 2,155 | 2,110 | 2,117 | -3 | -0.1% | 80,700 |
| 2024/03/15 | 2,107 | 2,134 | 2,091 | 2,120 | +16 | +0.8% | 56,200 |
| 2024/03/14 | 2,142 | 2,158 | 2,090 | 2,104 | -38 | -1.8% | 66,800 |
| 2024/03/13 | 2,150 | 2,182 | 2,115 | 2,142 | +3 | +0.1% | 65,700 |
| 2024/03/12 | 2,146 | 2,147 | 2,114 | 2,139 | +21 | +1% | 60,600 |
| 2024/03/11 | 2,081 | 2,118 | 2,081 | 2,118 | -25 | -1.2% | 75,000 |
| 2024/03/08 | 2,062 | 2,150 | 2,062 | 2,143 | +67 | +3.2% | 74,200 |
| 2024/03/07 | 2,039 | 2,085 | 2,039 | 2,076 | +47 | +2.3% | 70,900 |
| 2024/03/06 | 2,000 | 2,035 | 1,999 | 2,029 | +27 | +1.3% | 64,600 |
| 2024/03/05 | 2,028 | 2,031 | 2,002 | 2,002 | -19 | -0.9% | 51,600 |
| 2024/03/04 | 2,031 | 2,038 | 1,988 | 2,021 | -29 | -1.4% | 77,300 |
| 2024/03/01 | 2,082 | 2,094 | 2,029 | 2,050 | -37 | -1.8% | 71,800 |
| 2024/02/29 | 2,099 | 2,105 | 2,061 | 2,087 | -14 | -0.7% | 79,900 |
| 2024/02/28 | 2,079 | 2,108 | 2,060 | 2,101 | +62 | +3% | 74,600 |
| 2024/02/27 | 2,058 | 2,071 | 2,033 | 2,039 | -19 | -0.9% | 52,500 |
| 2024/02/26 | 2,058 | 2,094 | 2,040 | 2,058 | ±0 | ±0% | 53,500 |
| 2024/02/22 | 2,103 | 2,103 | 2,056 | 2,058 | -6 | -0.3% | 58,800 |
| 2024/02/21 | 2,100 | 2,111 | 2,055 | 2,064 | +13 | +0.6% | 75,000 |
| 2024/02/20 | 2,040 | 2,071 | 2,024 | 2,051 | +6 | +0.3% | 68,900 |
| 2024/02/19 | 1,950 | 2,048 | 1,950 | 2,045 | +83 | +4.2% | 106,500 |
| 2024/02/16 | 1,940 | 1,970 | 1,940 | 1,962 | +30 | +1.6% | 56,300 |
| 2024/02/15 | 1,960 | 1,960 | 1,917 | 1,932 | -20 | -1% | 66,000 |
| 2024/02/14 | 1,955 | 1,959 | 1,946 | 1,952 | -3 | -0.2% | 43,900 |
| 2024/02/13 | 1,977 | 1,977 | 1,945 | 1,955 | +5 | +0.3% | 77,500 |
| 2024/02/09 | 1,950 | 1,958 | 1,937 | 1,950 | +19 | +1% | 89,500 |
| 2024/02/08 | 1,905 | 1,946 | 1,896 | 1,931 | +29 | +1.5% | 91,500 |
| 2024/02/07 | 1,863 | 1,910 | 1,849 | 1,902 | +34 | +1.8% | 95,100 |
| 2024/02/06 | 1,910 | 1,910 | 1,840 | 1,868 | -45 | -2.4% | 186,000 |
| 2024/02/05 | 1,953 | 1,953 | 1,910 | 1,913 | -20 | -1% | 106,700 |
| 2024/02/02 | 1,969 | 1,969 | 1,918 | 1,933 | -46 | -2.3% | 114,700 |
| 2024/02/01 | 1,980 | 1,995 | 1,972 | 1,979 | -5 | -0.3% | 86,800 |
| 2024/01/31 | 1,973 | 1,993 | 1,958 | 1,984 | +9 | +0.5% | 53,500 |
| 2024/01/30 | 1,986 | 1,990 | 1,950 | 1,975 | -21 | -1.1% | 69,600 |
| 2024/01/29 | 2,000 | 2,024 | 1,979 | 1,996 | +8 | +0.4% | 76,700 |
| 2024/01/26 | 2,001 | 2,002 | 1,971 | 1,988 | -5 | -0.3% | 86,700 |
| 2024/01/25 | 1,959 | 2,000 | 1,957 | 1,993 | +52 | +2.7% | 136,900 |
| 2024/01/24 | 1,907 | 1,954 | 1,907 | 1,941 | +36 | +1.9% | 79,300 |
| 2024/01/23 | 1,885 | 1,917 | 1,880 | 1,905 | +24 | +1.3% | 70,600 |
| 2024/01/22 | 1,852 | 1,882 | 1,850 | 1,881 | +34 | +1.8% | 36,700 |
| 2024/01/19 | 1,872 | 1,872 | 1,839 | 1,847 | -27 | -1.4% | 38,300 |
| 2024/01/18 | 1,850 | 1,878 | 1,850 | 1,874 | +26 | +1.4% | 66,900 |
| 2024/01/17 | 1,861 | 1,879 | 1,847 | 1,848 | -13 | -0.7% | 79,400 |
| 2024/01/16 | 1,850 | 1,876 | 1,850 | 1,861 | +11 | +0.6% | 49,500 |
| 2024/01/15 | 1,831 | 1,855 | 1,825 | 1,850 | +15 | +0.8% | 82,400 |
| 2024/01/12 | 1,904 | 1,904 | 1,828 | 1,835 | +11 | +0.6% | 122,700 |
| 2024/01/11 | 1,856 | 1,863 | 1,812 | 1,824 | -27 | -1.5% | 85,700 |
301～
350
件表示中 / 1029件
類似銘柄と比較する
現在ご覧いただいている「あすかＨＤ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| あすかＨＤ | 233,000円 | +16.9% | +33.2% | 2.36% | 12.71倍 | 1.01倍 |
|
武田と親密。婦人科領域に強い。先発品比率引き上げに注力。２１年春にあすか製薬が持株会社化 |
| ネクセラファーマ | 92,000円 | +20.3% | - | 0.00% | 163.12倍 | 1.22倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 55,400円 | +14.3% | - | 3.61% | 22.50倍 | 1.44倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| タウンズ | 56,800円 | +4.6% | +6.1% | 4.93% | 9.68倍 | 3.58倍 |
|
院内で行う迅速抗原検査の体外診断薬専業大手。新型コロナ、インフルなど呼吸器感染症首位 |
| ヘリオス | 54,100円 | +150.0% | - | 0.00% | - | 26.61倍 |
|
ｉＰＳ細胞、体性幹細胞を活用する再生医薬品バイオベンチャー。住友ファーマと共同開発も |
市場注目の銘柄
チャート関連のコラム
